Marker combinations currently used in our laboratory for MRD studies in B-lineage ALL incorporating the top 10 differentially expressed markers discovered in this study
| FITC . | PE . | PerCP . | Allophycocyanin . | PE-Cy7 . | APC-H7 . | Horizon v450 . |
|---|---|---|---|---|---|---|
| CD38 | CD24* | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD38 | CD58 | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD38 | CD73* | CD34 | CD19 | CD10 | CD45 | CD15 |
| CD38 | CD200* | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD66c | CD123* | CD34 | CD19 | CD10 | CD45 | CD86* |
| CD72* | CD13 | CD34 | CD19 | CD10 | CD45 | CD33 |
| CD79b* | HSPB1* | CD34 | CD19 | CD10 | CD45 | Bcl2* |
| FITC . | PE . | PerCP . | Allophycocyanin . | PE-Cy7 . | APC-H7 . | Horizon v450 . |
|---|---|---|---|---|---|---|
| CD38 | CD24* | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD38 | CD58 | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD38 | CD73* | CD34 | CD19 | CD10 | CD45 | CD15 |
| CD38 | CD200* | CD34 | CD19 | CD10 | CD45 | CD44* |
| CD66c | CD123* | CD34 | CD19 | CD10 | CD45 | CD86* |
| CD72* | CD13 | CD34 | CD19 | CD10 | CD45 | CD33 |
| CD79b* | HSPB1* | CD34 | CD19 | CD10 | CD45 | Bcl2* |
MRD indicates minimal residual disease; ALL, acute lymphoblastic leukemia; PerCP, peridin chlorophyll protein; and PE-Cy7, PE–Cyanine 7.
Marker from this study.